OmniActive self-affirms GRAS for OmniLean
The expert panel evaluated the ingredient in accordance with stringent US Food and Drug Administration (FDA) safety criteria, said the company.
“OmniLean is a novel, differentiated ingredient with huge opportunity due to its formula flexibility and versatility in the metabolic health, weight management and satiety categories,” said Lynda Doyle, Sr. VP of Global Marketing, OmniActive. “OmniLean comes backed by OmniActive’s robust clinical program and GRAS self-affirmation which positions it as a unique, safe and effective ingredient.”
The company launched OmniLean earlier this year at Engredea 2016 in Anaheim. The ingredient is report to help support metabolic health and was recently shown to reduce post prandial blood glucose and insulin in a human clinical trial in healthy individuals (Journal of Diabetes Research, doi: 10.1155/2016/7971831).
OmniLean is a free-flowing powder that can be used in tablets, capsules, powders and bars, said OmniActive in a release.
